Matthew Peter Anderson

Matthew Peter Anderson is an Associate Professor and Principal Investigator at Beth Israel Deaconess Medical Center, with Harvard Medical School affiliations in their Ph.D. Program. His research spans neuropathology, genetic neurological disorders, and molecular mechanisms of epilepsy/autism.

• Director of Neuropathology, Beth Israel Deaconess Medical Center
• Faculty, Harvard Medical School Ph.D. Program

Research Interests

His work focuses on:

• Cell Biology of Neurons & Glia
• Gene Expression in Neurological Diseases
• Synapse Function & Plasticity
• Systems Neuroscience of Autism and Epilepsy

Key Discoveries

Dr. Anderson's lab identified:

• First human genetic epilepsy model with defective synaptic pruning (Nature Medicine 2009)
• Molecular convergence of UBE3A and seizure-induced effects via Cbln1 repression (Nature 2017)
• Thalamic-specific sleep disorder mechanisms (PNAS 2005)

Scientific Recognition

• International Distinguished Dissertation Award (HHMI Investigator Michael Welsh collaboration)

Experimental Expertise

Leverages cutting-edge methods like:

• Cre-loxP conditional genetics
• Chemogenetics & optogenetics
• Brain slice electrophysiology
• Protein interaction network analysis
• AAV viral vector gene therapy